Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer

Supportive Care in Cancer

Volumn 17, Issue 8, 2009, Pages 1081-1088

  Schwartzberg, Lee S ^a   Cobb, Patrick ^a   Walker, Mark S ^a   Stepanski, Edward J ^a   Houts, Arthur C ^a  

^a Accelerated Community Oncology Research Network   (United States)

Author keywords

Adverse effects; Breast neoplasms; Capecitabine; Quality of life; Taxanes; Utilization

Indexed keywords

EID: 79955004159     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-008-0558-2     Document Type: Article

References (28)

1. Bigot A (1974) The relevance of American Life Satisfaction Indices for research on British subjects before and after retirement. Age Ageing 3:113-121. doi:10.1093/ageing/3.2.113
2. Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H (2001) Answering patients' needs: oral alternatives to intravenous therapy. Oncologist 6(Suppl 4):12-16. doi:10.1634/theoncologist.6-suppl-4-12
3. Chang VT, Hwang SS, Feuerman M, Kasimis BS, Thaler HT (2000) The memorial symptom assessment scale short form (MSAS-SF). Cancer 89:1162-1171. doi:10.1002/1097-0142(20000901)89:5<1162::AID-CNCR26>3.0.CO;2-Y
4. Cnaan A, Laird NM, Slasor P (1997) Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 16:2349-2380. doi:10.1002/(SICI)1097-0258(19971030)16:20<2349::AID- SIM667>3.0.CO;2-E
5. Coates AS, Hürny C, Peterson HF et al (2000) Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol 18:2768-3774
6. Derogatis LR, Melisaratos N (1983) The brief symptom inventory: an introductory report. Psychol Med 13:595-605
7. Diener E, Emmons RA, Larsen RJ, Griffin S (1985) The satisfaction with life scale. J Pers Assess 49:71-75. doi:10.1207/s15327752jpa4901-13
8. El Helw L, Coleman RE (2004) Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast 14:368-374. doi:10.1016/j.breast.2004.12.005
9. Fortner B, Okon T, Schwartzberg L, Tauer K, Houts AC (2003) The cancer care monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage 26:1077-1092. doi:10.1016/j.jpainsymman. 2003.04.003
10. Ghersi D, Wilcken N, Simes RJ (2005) A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 93:293-301. doi:10.1038/sj.bjc.6602680
11. Gralow JR (2005) Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 89(Suppl 1):S9-S15. doi:10.1007/s10549-005-0143-z
12. Hays RD, Sherbourne CD, Mazel RM (1993) The RAND 36-item health survey 1.0. Health Econ 2:217-227. doi:10.1002/hec.4730020305
13. Jackisch C (2006) HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist 11(Suppl 1):34-41. doi:10.1634/ theoncologist.11-90001-34
14. Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS et al (2007) Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 25:424-430. doi:10.1200/JCO.2005.05. 2597
15. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE et al (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059-2064. doi:10.1200/JCO.2005.04.7498
16. Littell RC, Pendergast J, Natarajan R (2000) Modelling covariance structure in the analysis of repeated measures data. Stat Med 19:1793-1819. doi:10.1002/1097-0258(20000715)19:13<1793::AID-SIM482>3.0.CO;2-Q
17. National Cancer Institute (2003) Common terminology criteria for adverse events v3.0 (CTC). National Cancer Institute
18. Navarro RP, Morrow T, Baran R (2002) Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Manag Care Interface 15:55-62
19. Neugarten BL, Havighurst RJ, Tobin SS (1961) The measurement of life satisfaction. J Gerontol 16:134-143
20. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E et al (1994) The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326-1336. doi:10.1016/0959-8049(94)90182-1
21. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander- Klar H, Coyle N et al (1994) Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 3:183-189. doi:10.1007/BF00435383
22. Roche Laboratories XELODA® (capecitabine) Tablets [package insert]. Roche Laboratories, Nutley, New Jersey, USA
23. Seidman AD, O'Shaughnessy J, Misset JL (2002) Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 7(Suppl 6):20-28. doi:10.1634/theoncologist.7-suppl-6-20
24. Smorenburg CH, Bontenbal M, Verweij J (2001) Capecitabine in breast cancer: current status. Clin Breast Cancer 4:288-293. doi:10.3816/CBC.2001.n.003
25. Tubiana-Hulin M (2005) How to maximize the efficacy of taxanes in breast cancer. Cancer Treat Rev 31(Suppl 4):S3-S9. doi:10.1016/S0305-7372(05)80002-7
26. Verma S, Clemons M (2007) First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy. Oncologist 12:785-797. doi:10.1634/theoncologist.12-7-785
27. Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27:23-44. doi:10.1016/j.clinthera.2005.01.005
28. Ware JE, Snow KK, Kosinski M, Gandek B (1993) SF-36 health survey: manual and interpretation guide. The Health Institute New England Medical Center, Boston